<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03847155</url>
  </required_header>
  <id_info>
    <org_study_id>KARIM-09-NICOTINE</org_study_id>
    <secondary_id>2014-003720-43</secondary_id>
    <nct_id>NCT03847155</nct_id>
  </id_info>
  <brief_title>Prevention of Nicotine Abstinence in Critically Ill Patients After Major Surgery</brief_title>
  <official_title>Prevention of Nicotine Abstinence in Critically Ill Patients After Major Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Ostrava</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Ostrava</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine whether the application of transdermal
      nicotine patches in critically ill patients after major surgery with nicotine abstinence
      condition is associated with a lower incidence of delirium.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients in a group with medical intervention receive nicotine patch within 24 hours after
      surgery. The nicotine patch is replaced every day. Delirium is evaluated every day by the
      Confusion Assessment Method (CAM) - ICU test. The maximum length of intervention is 7 days.

      Patients in a group with placebo receive a placebo patch within 24 hours after surgery. This
      patch is replaced every day. Delirium is evaluated in the same way - CAM - ICU test. The
      maximum length of the placebo intervention is 7 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The patients will be randomized into two study groups, with the active substance and placebo.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The participant, care provider and investigator will be masked as far as the treatment provided is concerned.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of delirium episodes</measure>
    <time_frame>maximum of 7 days</time_frame>
    <description>The number of delirium episodes, defined according to the CAM-ICU test, in the course of the seven days with the patch attached will be measured in both groups of study subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the number of days with delirium</measure>
    <time_frame>maximum of 7 days</time_frame>
    <description>Change in the number of days with delirium, defined according to the CAM-ICU test, by 20%, in the course of the seven days with the patch attached among the study subjects with the nicotine patch.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-hours</measure>
    <time_frame>maximum of 7 days</time_frame>
    <description>The number of ventilator-hours will be observed in both groups of study subjects.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>Nicotine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients randomized into this study arm will receive a medical intervention - nicotine patch for the period of a maximum of 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients randomized into this study arm will receive a placebo patch for the period of a maximum of 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine patch</intervention_name>
    <description>The patients will receive a nicotine patch for the period of a maximum of 7 days.</description>
    <arm_group_label>Nicotine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo patch</intervention_name>
    <description>The patients will receive a placebo patch for the period of a maximum of 7 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing a surgical procedure - urological, surgical, trauma surgery,
             orthopedic surgery, dental surgery)

          -  Age 18 years and above

          -  Patient with an assumption of nicotine abstinence (smoking a minimum 10
             cigarettes/day).

          -  Ex-smokers (if they stopped smoking less than 30 days prior to surgery)

          -  An assumption of hospitalization at the intensive care unit (ICU) after surgery

          -  Signed Informed consent

        Exclusion Criteria:

          -  Age ˂ 18 years

          -  Non-signing of the informed consent

          -  Patients after neurosurgical surgery, patients with traumatic brain injury, patients
             after a new stroke

          -  Patients with psychiatric diseases

          -  Nicotine, Curapor or Hydrocoll allergy

          -  Patient with a heart attack, unstable angina pectoris or patients with a serious heart
             arrhythmia

          -  Pregnant and breastfeeding patients

          -  Patients with nicotine treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Neiser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Ostrava</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Petr Vávra, Ass.Prof.,MD,PhD</last_name>
    <phone>0042059737</phone>
    <phone_ext>2544</phone_ext>
    <email>petr.vavra@fno.cz</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kateřina Vítková, RNDr.,PhD</last_name>
    <phone>0042059737</phone>
    <phone_ext>2052</phone_ext>
    <email>katerina.vitkova@fno.cz</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Ostrava</name>
      <address>
        <city>Ostrava</city>
        <state>Moravian-Silesian Region</state>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Vávra, Ass.Prof.,MD,PhD</last_name>
      <phone>0042059737</phone>
      <phone_ext>2544</phone_ext>
      <email>petr.vavra@fno.cz</email>
    </contact>
    <contact_backup>
      <last_name>Kateřina Vítková, RNDr.,PhD</last_name>
      <phone>0042059737</phone>
      <phone_ext>2052</phone_ext>
      <email>katerina.vitkova@fno.cz</email>
    </contact_backup>
    <investigator>
      <last_name>Jan Neiser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kateřina Tejkalová, Mgr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <link>
    <url>http://www.surgicalcriticalcare.net/Guidelines/delirium_2011.pdf</url>
    <description>Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit</description>
  </link>
  <reference>
    <citation>Granberg Axèll AI, Malmros CW, Bergbom IL, Lundberg DB. Intensive care unit syndrome/delirium is associated with anemia, drug therapy and duration of ventilation treatment. Acta Anaesthesiol Scand. 2002 Jul;46(6):726-31.</citation>
    <PMID>12059899</PMID>
  </reference>
  <reference>
    <citation>Bledowski J, Trutia A. A review of pharmacologic management and prevention strategies for delirium in the intensive care unit. Psychosomatics. 2012 May-Jun;53(3):203-11. doi: 10.1016/j.psym.2011.12.005. Epub 2012 Apr 4. Review.</citation>
    <PMID>22480622</PMID>
  </reference>
  <reference>
    <citation>Cartin-Ceba R, Warner DO, Hays JT, Afessa B. Nicotine replacement therapy in critically ill patients: a prospective observational cohort study. Crit Care Med. 2011 Jul;39(7):1635-40. doi: 10.1097/CCM.0b013e31821867b8.</citation>
    <PMID>21494111</PMID>
  </reference>
  <reference>
    <citation>Jablonski J, Gray J, Miano T, Redline G, Teufel H, Collins T, Pascual-Lopez J, Sylvia M, Martin ND. Pain, Agitation, and Delirium Guidelines: Interprofessional Perspectives to Translate the Evidence. Dimens Crit Care Nurs. 2017 May/Jun;36(3):164-173. doi: 10.1097/DCC.0000000000000239.</citation>
    <PMID>28375992</PMID>
  </reference>
  <reference>
    <citation>Van Rompaey B, Schuurmans MJ, Shortridge-Baggett LM, Truijen S, Elseviers M, Bossaert L. A comparison of the CAM-ICU and the NEECHAM Confusion Scale in intensive care delirium assessment: an observational study in non-intubated patients. Crit Care. 2008;12(1):R16. doi: 10.1186/cc6790. Epub 2008 Feb 18.</citation>
    <PMID>18282269</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>February 18, 2019</study_first_submitted>
  <study_first_submitted_qc>February 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2019</study_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nicotine patch</keyword>
  <keyword>placebo</keyword>
  <keyword>critically ill patients</keyword>
  <keyword>delirium</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The investigators do not plan to make individual participant data available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

